|
|
Insulet Corporation (NASDAQ: PODD) |
|
Price: $147.4800
$-3.10 
-2.059%
|
| Day's High:
| $150.55999755859375
| Week Perf:
| -0.79 %
|
| Day's Low: |
$ 145.42 |
30 Day Perf: |
5.87 % |
| Volume (M): |
1,058,427 |
52 Wk High: |
$ 354.88 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$233.25 |
| Open: |
$149.32 |
52 Wk Low: |
$126.40 |
|
|
| Market Capitalization (Millions $) |
10,353 |
| Shares
Outstanding (Millions) |
70 |
| Employees |
5,400 |
| Revenues (TTM) (Millions $) |
2,901 |
| Net Income (TTM) (Millions $) |
303 |
| Cash Flow (TTM) (Millions $) |
-803 |
| Capital Exp. (TTM) (Millions $) |
232 |
Business Description
Insulet Corporation is a medical technology company that was founded in 2000 and is headquartered in Acton, Massachusetts. The company specializes in developing and manufacturing insulin delivery systems for people with diabetes.
One of Insulet Corporation's main products is the Omnipod insulin management system, which is a tubeless, wearable insulin pump that delivers continuous insulin for people with Type 1 diabetes. The Omnipod system consists of two components: a pod that is worn on the body and a handheld device that is used to control the pod.
The Omnipod system is unique in that it is wireless and completely tubeless, making it more discreet and flexible than other insulin pumps on the market. The system also uses a proprietary algorithm that adjusts insulin delivery based on a user's glucose levels in real-time, making it more precise and effective for managing diabetes.
In addition to the Omnipod system, Insulet Corporation also offers a range of accessories and supplies to help people with diabetes manage their insulin therapy. These include test strips, lancets, and glucose meters.
Insulet Corporation is committed to innovation and is constantly developing new products and technologies to improve the lives of people with diabetes. The company has a team of engineers, scientists, and healthcare professionals who work together to research, develop, and bring new products to market.
Overall, Insulet Corporation is a leading medical technology company that is dedicated to helping people with diabetes manage their condition more effectively and efficiently. Their innovative products and commitment to patient care have made them a trusted name in the diabetes community.
Company Address: 100 Nagog Park Acton 1720 MA
Company Phone Number: 600-7000 Stock Exchange / Ticker: NASDAQ PODD
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, Jan 14 2025 7:53 AM UTC
In a significant advancement for diabetes management, Insulet Corporation, a pioneer in tubeless insulin pump technology headquartered in Acton, Massachusetts, has announced the commercial launch of its revolutionary Omnipod 5 Automated Insulin Delivery System in five additional countries across Europe: Italy, Denmark, Finland, Norway, and Sweden. This move marks another ste...
|
| Business Update
Published Fri, Nov 1 2024 2:12 PM UTC
As November unfolds, Insulet Corporation, a pioneer in tubeless insulin pump technology, is poised to make significant strides in enhancing diabetes management and raising awareness during National Diabetes Awareness Month and World Diabetes Day. The company is renowned for its innovative Omnipod brand of products, which are transforming the landscape of insulin delivery for...
|
| Business Update
Published Tue, Aug 27 2024 1:16 AM UTC
Insulet Corporation (NASDAQ: PODD), a pioneer in tubeless insulin pump technology, has reached significant milestones that enhance its position in the diabetes management industry. The recent U.S. Food and Drug Administration (FDA) clearance for Insulet’s Omnipod 5 Automated Insulin Delivery (AID) System for use in adults with type 2 diabetes, together with the opening of ...
|
| Business Update
Published Mon, Aug 26 2024 9:09 PM UTC
In a landmark moment for diabetes management, Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology, has announced that its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now FDA-cleared for use by people with type 2 diabetes aged 18 and above. This marks it as the first and only Automated Insulin Delivery (AID) system to receive...
|
| Business Update
Published Wed, Aug 14 2024 9:47 AM UTC
Insulet Opens New Manufacturing Facility in Malaysia, Expanding Reach of Innovative Diabetes Care Solutions In a significant stride toward enhancing diabetes management worldwide, Insulet Corporation celebrated the grand opening of its expansive 400,000-square-foot manufacturing facility in Johor Bahru, Malaysia. The event marks a pivotal milestone for the ACTON, Massachuset...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
4.25 $ |
| Revenues (TTM) |
41.32 $
|
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
18.56 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
537,185 |
| Net
Income per Employee (TTM) |
56,074 |
| Receivable Turnover Ratio (TTM) |
6.93 |
| Inventory Turnover Ratio (TTM) |
1.86 |
| Asset Turnover Ratio (TTM) |
0.92 |
|
|
| Per Share |
|
| Earnings (TTM) |
4.25 $
|
| Revenues (TTM) |
41.32 $ |
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
18.56 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| U S |
|
 68.11 % |
of total Revenue |
| International |
|
31.89 % |
of total Revenue |
| Total Omnipod products |
|
99.57 % |
of total Revenue |
| Drug Delivery |
|
0.43 % |
of total Revenue |
| |
On August 9 2024 the Insulet provided following guidance
nnInsulet Corporationnn Reports Impressive Revenue Growth for Second Quarter 2024
nnACTON, Massachusettsnn – Insulet Corporation (NASDAQ: PODD), a preeminent innovator in tubeless insulin pump technology known for its Omnipod product line, has released its financial results for the second quarter of 2024, showcasing a notable revenue increase.
For the period ending June 30, 2024, Insulet achieved a remarkable revenue of $488.5 million, reflecting a 23.2% rise compared to $396.5 million reported during the same quarter the previous year. When adjusted for constant currency, the revenue growth stands even higher at 23.4%. This significant uptick not only highlights the company’s robust pe...
|
|
|
14.85%